A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected subjects treated with HAART

Trial Profile

A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected subjects treated with HAART

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2011

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Sponsors Abbott Healthcare Products
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2010 Actual number of patients (51) added as reported by ClinicalTrials.gov record.
    • 21 Apr 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top